Categories News Press Releases Archives 2025 December November October September August July June May April March February January 2024 December November October September August July June May April March February January 2023 December November October September August July June April March February January 2022 December November September August June May March February January 2021 December November October September August May April February Jun 27 UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis Read More Share:| | | Jun 01 Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community Read More Share:| | | Apr 20 UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting Read More Share:| | | Jan 06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Read More Share:| | | Nov 14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients Read More Share:| | | Sep 22 UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting Read More Share:| | | Jun 01 Life with MG & What I Wish For Everyone Who is Diagnosed Read More Share:| | | May 27 My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis Read More Share:| | | May 10 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis Read More Share:| | | Feb 04 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results Read More Share:| | | Pagination First page Previous page ‹ Previous Page 1 Current page 2 Page 3 Next page Next › Last page